Literature DB >> 16922507

Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites.

Maria Mitsi1, Zhenning Hong, Catherine E Costello, Matthew A Nugent.   

Abstract

Regulation of angiogenesis involves interactions between vascular endothelial growth factor (VEGF) and components of the extracellular matrix, including fibronectin and heparan sulfate. In the present study, we identified two classes of VEGF binding sites on fibronectin. One was constitutively available whereas the availability of the other was modulated by the conformational state of fibronectin. Atomic force microscopy studies revealed that heparin and hydrophilic substrates promoted the extended conformation of fibronectin, leading to increased VEGF binding. The ability of heparin to enhance VEGF binding to fibronectin was dependent on the chemical composition and chain length of heparin, since long (>22 saccharides) heparin chains with sulfation on the 6-O and N positions of glucosamine units were required for full activity. Treatment of the complex endothelial extracellular matrix with heparin also increased VEGF binding, suggesting that heparin/heparan sulfate might regulate VEGF interactions within the extracellular matrix by controlling the structure and organization of fibronectin matrices.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16922507     DOI: 10.1021/bi060974p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  50 in total

1.  Contribution of unfolding and intermolecular architecture to fibronectin fiber extensibility.

Authors:  Mark J Bradshaw; Michael L Smith
Journal:  Biophys J       Date:  2011-10-05       Impact factor: 4.033

2.  Sweet cues: How heparan sulfate modification of fibronectin enables growth factor guided migration of embryonic cells.

Authors:  Karen Symes; Erin M Smith; Maria Mitsi; Matthew A Nugent
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

Review 3.  Fibronectin Interaction and Enhancement of Growth Factors: Importance for Wound Healing.

Authors:  Katarzyna M Sawicka; Markus Seeliger; Tagai Musaev; Lauren K Macri; Richard A F Clark
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-08-01       Impact factor: 4.730

Review 4.  Heparan sulfate-protein binding specificity.

Authors:  M A Nugent; J Zaia; J L Spencer
Journal:  Biochemistry (Mosc)       Date:  2013-07       Impact factor: 2.487

5.  Conformational remodeling of the fibronectin matrix selectively regulates VEGF signaling.

Authors:  Anthony Ambesi; Paula J McKeown-Longo
Journal:  J Cell Sci       Date:  2014-06-30       Impact factor: 5.285

6.  Collagen-gelatin mixtures as wound model, and substrates for VEGF-mimetic peptide binding and endothelial cell activation.

Authors:  Tania R Chan; Patrick J Stahl; Yang Li; S Michael Yu
Journal:  Acta Biomater       Date:  2015-01-10       Impact factor: 8.947

7.  Hypoxia modulates the development of a corneal stromal matrix model.

Authors:  Albert Lee; Dimitrios Karamichos; Obianamma E Onochie; Audrey E K Hutcheon; Celeste B Rich; James D Zieske; Vickery Trinkaus-Randall
Journal:  Exp Eye Res       Date:  2018-02-27       Impact factor: 3.467

8.  PDGF-A interactions with fibronectin reveal a critical role for heparan sulfate in directed cell migration during Xenopus gastrulation.

Authors:  Erin M Smith; Maria Mitsi; Matthew A Nugent; Karen Symes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

9.  A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

10.  Advances in biomimetic regeneration of elastic matrix structures.

Authors:  Balakrishnan Sivaraman; Chris A Bashur; Anand Ramamurthi
Journal:  Drug Deliv Transl Res       Date:  2012-10       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.